Evidence map›Paper›PMID 31913556›Full record

ArticleJournal of the International AIDS Society2020

New opportunities in tuberculosis prevention: implications for people living with HIV.

Lucia González Fernández, Esther C Casas, Satvinder Singh, Gavin J Churchyard, Grania Brigden, Eduardo Gotuzzo, Wim Vandevelde, Suvanand Sahu, Sevim Ahmedov, Adeeba Kamarulzaman and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 7 countries.

Lucia González FernándezHIV Co-Infections and Co-Morbidities, The International AIDS Society, Geneva, Switzerland.ORCID 0000-0003-0531-2698
Esther C CasasSouthern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa.ORCID 0000-0003-4141-2397
Satvinder SinghHIV Department, World Health Organization, Geneva, Switzerland.
Gavin J ChurchyardAurum Institute, Parktown, South Africa.
Grania BrigdenDepartment of Tuberculosis, International Union Against Tuberculosis and Lung Disease, Geneva, Switzerland.
Eduardo GotuzzoDepartment of Medicine and Director of the "Alexander von Humboldt" Institute of Tropical Medicine and Infectious Diseases, Peruvian University Cayetano Heredia, Lima, Peru.
Wim VandeveldeGlobal Network of People living with HIV (GNP+), Cape Town, South Africa.
Suvanand SahuStop TB Partnership, Geneva, Switzerland.
Sevim AhmedovBureau for Global Health, Infectious Diseases, TB Division, USAID, Washington, DC, USA.
Adeeba KamarulzamanDepartment of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Alfredo Ponce-de-LeónInfectious Diseases Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Beatriz GrinsztejnInstituto Nacional de Infectologia Evandro Chagas, Fiocruz, Brazil.
Susan SwindellsUniversity of Nebraska Medical Center, Omaha, NE, USA.
Instituto Evandro Chagas · BRInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXInternational AIDS Society · CHMédecins Sans Frontières · ZASouth African Medical Research Council · ZAUnion for International Cancer Control · CHUnited States Agency for International Development · USUniversidad Peruana Cayetano Heredia · PEUniversity of Malaya · MYUniversity of Nebraska Medical Center · USWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

introductionTuberculosis (TB) is a leading cause of mortality among people living with HIV (PLHIV). An invigorated global END TB Strategy seeks to increase efforts in scaling up TB preventive therapy (TPT) as a central intervention for HIV programmes in an effort to contribute to a 90% reduction in TB incidence and 95% reduction in mortality by 2035. TPT in PLHIV should be part of a comprehensive approach to reduce TB transmission, illness and death that also includes TB active case-finding and prompt, effective and timely initiation of anti-TB therapy among PLHIV. However, the use and implementation of preventive strategies has remained deplorably inadequate and today TB prevention among PLHIV has become an urgent priority globally. DISCUSSION: We present a summary of the current and novel TPT regimens, including current evidence of use with antiretroviral regimens (ART). We review challenges and opportunities to scale-up TB prevention within HIV programmes, including the use of differentiated care approaches and demand creation for effective TB/HIV services delivery. TB preventive vaccines and diagnostics, including optimal algorithms, while important topics, are outside of the focus of this commentary.

conclusionsA number of new tools and strategies to make TPT a standard of care in HIV programmes have become available. The new TPT regimens are safe and effective and can be used with current ART, with attention being paid to potential drug-drug interactions between rifamycins and some classes of antiretrovirals. More research and development is needed to optimize TPT for small children, pregnant women and drug-resistant TB (DR-TB). Effective programmatic scale-up can be supported through context-adapted demand creation strategies and the inclusion of TPT in client-centred services, such as differentiated service delivery (DSD) models. Robust collaboration between the HIV and TB programmes represents a unique opportunity to ensure that TB, a preventable and curable condition, is no longer the number one cause of death in PLHIV.

Indexed as

Anti-Retroviral AgentsAntitubercular AgentsDrug InteractionsHIV InfectionsHumansRifamycinsTuberculosisAnti-Retroviral AgentsAntitubercular AgentsRifamycinsco-infectiondifferentiated careHV care continuumpublic healthTBtreatment

Identifiers

PMID31913556
PMCPMC6947976
OpenAlexW3000607851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.